• Unrestricted DAA access improves HCV treatment uptake among PWIDs

    9 days ago - By Healio

    Data from Australia's annual bio-behavioral surveillance of people who inject drugs attending needle syringe programs between 2015 and 2017 showed a significant increase in treatment uptake and decrease in viremic prevalence, especially among older patients and those with a history of opioid substitution therapy.
    “Australia implemented unrestricted subsidized access to therapy in March 2016, ensuring that all adults with chronic HCV were eligible for DAA therapy irrespective of liver disease stage and ongoing drug use,” Jenny Iverson, PhD, from
    Read more ...